Last reviewed · How we verify
Experimental Cyclic Regimen
Experimental Cyclic Regimen works by targeting a specific molecular pathway to modulate cellular behavior.
Experimental Cyclic Regimen works by targeting a specific molecular pathway to modulate cellular behavior. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Experimental Cyclic Regimen |
|---|---|
| Also known as | three separate 6 month cycles of daily Forteo, each followed by one of Prolia |
| Sponsor | Health Research, Inc. |
| Drug class | Small molecule |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of action is not fully understood, but it is believed to involve a complex interplay of molecular interactions that ultimately lead to the desired therapeutic effect.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE2)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |